Screener
Cogent Biosciences, Inc. COGT Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfDebt.
The source filing: Cogent Biosciences, Inc.’s 10-K, filed February 17, 2026.
- Filed
- Feb 17, 2026, 9:24 AM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-053334
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Net cash provided by (used in) investing activities | (399,526) | 38,276 | (97,824) |
| Cash flows from financing activities: | |||
| Proceeds from long-term debt | 49,291 | — | — |
| Repayment of long-term debt | (54,635) | — | — |
| Proceeds from convertible senior notes | 223,100 | — | — |
| Payment of debt issuance costs | (2,622) | — | — |
| Proceeds from issuance of common stock in public offerings, net of offering costs of $35.3 million | 539,776 | — | — |
| Proceeds from issuance of common stock in public offering, net of offering costs of $10.7 million | — | — | 161,819 |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Cogent Biosciences, Inc.'s debt repayments?
- Cogent Biosciences, Inc. (COGT) reported debt repayments of $13.66M in Q4 2025.
- What does debt repayments mean?
- Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.
Ask your AI about Cogent Biosciences, Inc.'s debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude